HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: L’Oreal Acquires IT Cosmetics, Provides Microbeads Update; More

This article was originally published in The Rose Sheet

Executive Summary

L’Oreal adds IT Cosmetics to its thriving Luxe business for $1.2bn in cash. Unilever offers perspective on its Dollar Shave Club acquisition during its Q1 earnings call.

You may also be interested in...



L'Oreal's Q3 Driven By Luxe Gains, With China Cited As Engine

French beauty giant books luxury division sales growth of 8.9% to $2.35bn in its third quarter, and 13.2% growth to $7.16bn for the nine months ended Sept. 30. Increased consumption of luxury skin care and makeup in China has been a key driver of the firm's results in fiscal 2017, according to L'Oreal execs.

L’Oreal Picks Up CeraVe Skin Care Via $1.3bn Deal With Valeant

The CeraVe, AcneFree and Ambi skin-care lines will change hands from Valeant Pharmaceuticals to L’Oreal under a deal announced Jan. 10, beefing up the latter’s dermatologist-aligned Active Cosmetics division.

‘Serial Acquirers’ In Cosmetics Sector Create More Value – A.T. Kearney Report

The enterprise-value growth rate of beauty and personal-care players that completed two or more acquisitions annually during the 2010-2016 period is 26% higher than that for less frequent buyers, the consulting firm notes in a recent report. Translation: “Shop or Drop,” its analysts say.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108465

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel